Latest Zoono (ASX:ZNO) News

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Zoono Group has boosted its cash receipts by NZ$333,000 this quarter, driven by initial orders worth NZ$585,000 in its fresh food shelf-life extension sector. Despite operating losses, the company expects to sustain operations through signed contracts and inventory.

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

Zoono Group Limited has responded to ASX queries confirming ongoing collaboration with OSY Group Limited, acknowledging delays in meeting sales targets but highlighting steady contract progress and future order potential.

Zoono Group Limited has clarified the recent spike in its share price and trading volume, linking it to a new South African packaging agreement and a freshly announced contract with Multisteps Pty Ltd.

Zoono Group has signed a five-year exclusive contract with Multisteps Pty Limited to apply its antimicrobial technology to fresh produce packaging in Australia, aiming to reduce food waste and boost sustainability.

Zoono Group has secured a five-year exclusive contract with Mpact Operations to apply its antimicrobial technology to corrugated packaging for fresh produce in South Africa and Namibia, aiming to extend shelf-life and reduce food waste.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 50 active trials worldwide and anticipates its first significant sales this quarter, supported by fresh funding and expanding market interest.

Zoono Group Limited has responded to an ASX price query following a recent surge in its share price and trading volume, confirming no undisclosed information exists and attributing market activity to ongoing shelf-life extension trials across multiple continents.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Zoono Group Limited has raised an additional A$992,000 through a shortfall placement, boosting its working capital to support global expansion of its shelf-life extension technology. The company also linked CEO share incentives to ambitious sales targets, signaling confidence in growth prospects.

Zoono Group Limited has closed its recent rights issue, raising $785,000 with a significant shortfall remaining. Managing Director Paul Hyslop fully subscribed and may provide further financial support as the company targets growth in Asia and product innovation.